Member Info for CHELSEA7

5 Trades.............All Sells

2cvguy, glad DA posted that actually, haven"t listened to it since it was recorded. Maybe i will have a quite word with CH and ask him how long is near term?, lol.

Talking of CH I"ve had a couple of e-mail exchanges with him now, very charming man, replies quickly as RG did, and one of the exchanges he went out of way to reply, when no question was asked but offered him a few observations. I get a good feeling about him, he has a good sense of humour too.

Good research DA, about 9 minutes in CH mentions the near term, worth hearing his explanation of Grand Challenge just prior to 7 minutes, and the whole interview is worth watching again as a reminder. Thanks.

The near term has actually been mentioned a couple of times, 2cvguy made me laugh with the "very near term" reminder, it did cause "some debate".

Wonder who is barking up the wrong tree, again, lol.

Morning 2cvguy, I think it was near term, yeah i got told off for that, lol. Well we have the same strategy for sure, just hoping it comes sooner . atb

Presuming the AGM is being held in Oxford again, think i will as in previous years make a couple of calls next week and find out what date we are provisionally booked in on. Start time as in others is usually after lunch, and i think this year a fair few of us intend to go, so it will probably be in the bigger of the two conference rooms this time as the first at Oxford F.C.

It is the first opportunity since last year to discuss the spate of RNS received last December/January, the impending SBIB1/2 trial dates and of course The Grand Challenge itself so regardless of getting a new RNS or not, there is plenty to discuss. I rather think with so much to discuss many questions we have in our minds will be covered, so really hoping for a very productive afternoon, and it does play on my mind that a few items that could of been RNS reached have not, indicating to me that raising the share price hasn"t/and is not a priority as in recent times. I rather choose to feel that bigger news is not too far off, which will act as inflection points on there own merit.

The Grand Challenge has surprised me, with regards to a certain apathy towards it, it is not often such an opportunity is afforded, and regardless of whether we win, some very big relationships will have been forged over the course of this year, which we all hope will lead to commercial activity. So its a pretty important day, and i feel many questions on peoples minds will be addressed and hope we use the time allowed well and positively.

I mentioned TOOP earlier, up from .20 this morning to .90/.95 at the close after a contract win. Down from highs of around 1.25 it will be interesting to read posts prior to today, point being it is the same company today as it was yesterday, just allowed to drift awaiting news. It is my hope that will soon be us, and yet another example the SP bears little relation to current activities. So hope we make it a special day, there is enough material to ensure that.

A few niggly posts tonight, lets cut that out quick, and if Twitter is so superior, i have no views, suggest people stay there rather than dump on here. Been sleeping for 20 odd hours a day for three weeks, looks like a sleepness night, much to catch up on and do.

Inanaco, as i have said many times we are seeing clinical development and big improvements to the platform. Frustrating for shareholders, particularly traders, but we shall see the benefits i am sure.

Delighted twitter is satisying others needs, don"t particularly like being labelled stupid as to my choices, and as i have indicated the BB is better without Hotwings and ONW going personal on you, seems others feel the need to continue that. Shame. Lets see what tomorrow brings......................

That"s why i would like to go to this AGM, not doing too well in getting a lift though.

Inanaco have only been complimentary about your input here for many weeks, but i make one post and you respond with..................""..the point being C7 ... everybody knows the trial process takes years, so you feel stating the obvious is a great post ?""

Well who claimed it was a great post?? And as you know that your price forecasts, were very early and wrong. I know quite a few are posting on twitter, and i declined only to free myself up, unfortunately i have neither the energy or desire to spend time on other shares which i have no intention of trading.

Decent portfolios take time and money to build, unfortunately my income streams ended seven years ago. If that makes me stupid too Ivy then so be it. Happy to hold here, after a long time building a holding that is significant to me. Thats all that is important to me, . still hopeful and yes we are better placed, pretty sure the names working with us wouldn"t be doing so without very good reason.

Very few posts are irrelevant, they all help in having an opinion.

I have stated mine, and am not saying we will have to wait ten years, but his point was it takes time for a bio like us, and it has. Goodnight.

Understand those thoughts. I would have liked to see developments happen quicker, but i liked leas post some weeks ago where he mentioned often it takes ten years to create true value commercially.

Moditope is just six years old in that cycle, and i do believe we are far better placed than we were two years ago. Just holding tight now, we have an interesting couple of months ahead for sure.

I notice TOOP was .20p this morning, now sitting at .90/,95 after a contract win. We can but hope, but i don"t believe our team in Grand Challenge doesn"t hold a massive belief in Moditope. Take care.

Ivy..................."" some of the failures of SCLP to progress their own stated objectives""

Is it really failure, or just the time needed for clinical development??

Ruck a very relavent point, one which we can be sure Scancell are very aware of, as we all are.

Some very good posts here of late IMHO enhanced by the absence of Hotwings and ONW.

Deadly, sorry i didnt answer your question the other day, i think Inanaco and Ray have covered that very well. Take care all.

Hi Roses, no, sorted out a few issues. Take care.

I think Scancell are heading towards a deal , as per our stratagy at the minute. Lets see what happens with the Grand Challenge results.

Some people have expressed their doubts as to the business accumen of the BOD in sealing and negotiating commercial deals I wonder how people feel now as it becomes clear to me(IMHO) that Chiplin has installed a stratagy to make us a commercial target.

Haven"t had an opportunity yet to research Affirmed, subject to an impressive deal today with Genentech, except for what has been published, but there certainly seems similarities in the direction we are moving towards, and have been for some time.

Any views on this?

As you posted yesterday............................

Nobody seems to understand the value of a complete new class of cancer antigen

a suite of them ...

when pretty well every deal done in this area, is money invested in antigen discovery .....

Very true

Genentech is handing over $96 million (€82 million) in upfront and near-term payments to work with Affimed on NK and T cell engagers. The deal features $5 billion in milestones and royalties that could land in Affimed’s bank account if the immunotherapies succeed.

Affimed has built its business upon a platform that generates multispecific NK and T cell engagers. The drugs are designed to redirect innate and adaptive immune cells and thereby orchestrate attacks on tumors. For example, Affimed’s lead candidate AFM13 is a bispecific antibody that binds to CD30 on tumors and to CD16A to recruit and activate NK cells.

Germany’s Affimed has struggled to catch the wave of interest in immuno-oncology drugs, causing its market cap to slip below $100 million. But Roche's Genentech likes the look of the platform and has reignited interest in the company.

This collaboration is based on Affimed's innate immune cell drug discovery and development expertise and our team's deep understanding of cancer immunology," Roche partnering chief James Sabry, M.D., Ph.D., said in the announcement.

In return for its $96 million outlay, Genentech has secured the chance to work with Affimed on the discovery- and research-stage testing of immune cell engagers. Affimed is contributing candidates generated by its platform to the alliance and agreeing to work on multiple solid and hematological tumor targets.

Once a candidate advances beyond late-stage research, Genentech will take sole control and guide it through clinical development and, potentially, commercialization. As it does so, the Roche subsidiary will hand over a growing slice of the $5 billion in milestones and royalties.

The validation of Genentech and potential for the deal to add significantly to Affimed’s coffers has triggered a surge in investor interest in the German biotech. Shares in Affimed were up more than 140% in premarket trading.

There has been a couple of items arguably that could have been RNSed. Wonder if they are saving it for a big one, soon?

One day it will be Scancell................................

This may have seemed beyond optimistic. Not only was Michael past last chances in terms of conventional therapy, his intestines had been left so ravaged by previous doses of radiotherapy to kill tumours there that his gut was perforated, causing him crippling stomach infections. He was so ill there was little point subjecting him to abdominal surgery to repair this.

Indeed, Michael was so ill that after only ten intravenous doses of the experimental drug pembrolizumab (branded as Keytruda), administered once every three weeks, he was taken off the trial. To complete the therapy he should have received a further 29 doses.

Nevertheless, Professor de Bono’s team gave him MRI scans to check his progress — and found his tumour had disappeared.

That was in April last year. Destroying the cancer rendered Michael strong enough to receive the stomach surgery he needed. He had another cancer scan last week and he’s still clear. ‘It is absolutely incredible,’ he says.

Professor de Bono describes Michael’s result as ‘profound and spectacular’.

What’s more, this science could be repeated in future for millions of patients, experts believe.

What made Michael, despite his frailty, such a good candidate for the trial is the fact that his cancer had aggressively mutated its DNA several times to evade conventional treatment — making it a good test for pembrolizumab’s mutation-targeting powers.

Good link keiny

Very good posts, guess he had to go out, lol.

"""Unless something unexpected comes along."""

Do you mean Biontech, Genentech, Roche, Karolinska Institute, Cruk, Possibly £20m to further fund Moditope, or John Glencross confirmatory tweet that SCIB 1 Combo Trial WILL start by year end?????